Arnold J J Reuser1, Maarten R Drost. 1. Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands. a.reuser@erasmusmc.nl
Abstract
UNLABELLED: Between 40 and 50 lysosomal storage disorders are known at present. Fine details of the pathogenic process involved are in general not known. This overview highlights the basic principles of lysosomal pathogenesis and the clinical consequences of defective genes involved in lysosomal functions. The subject is discussed in the context of the possibility of prevention and reversal of cellular and organ damage by enzyme replacement therapy. Also presented is a mechanical model for the muscle pathology observed in Pompe disease. Direct mechanical effects of the non-contractile inclusions - glycogen-loaded lysosomes - seem to be a key factor in the loss of force during both early and late stages of the disease. CONCLUSION: Each lysosomal storage disorder and each patient with a given lysosomal disorder has unique molecular, pathological and clinical features. But, the order of pathological events is largely the same. Mutations in a gene cause lysosomal dysfunction which, in turn, results in cellular pathology affecting organ structure and function. Clinical symptoms are the ultimate manifestation. The reversibility of symptoms with enzyme replacement therapy will vary according to the disease, as well as the nature and stage of organ pathology.
UNLABELLED: Between 40 and 50 lysosomal storage disorders are known at present. Fine details of the pathogenic process involved are in general not known. This overview highlights the basic principles of lysosomal pathogenesis and the clinical consequences of defective genes involved in lysosomal functions. The subject is discussed in the context of the possibility of prevention and reversal of cellular and organ damage by enzyme replacement therapy. Also presented is a mechanical model for the muscle pathology observed in Pompe disease. Direct mechanical effects of the non-contractile inclusions - glycogen-loaded lysosomes - seem to be a key factor in the loss of force during both early and late stages of the disease. CONCLUSION: Each lysosomal storage disorder and each patient with a given lysosomal disorder has unique molecular, pathological and clinical features. But, the order of pathological events is largely the same. Mutations in a gene cause lysosomal dysfunction which, in turn, results in cellular pathology affecting organ structure and function. Clinical symptoms are the ultimate manifestation. The reversibility of symptoms with enzyme replacement therapy will vary according to the disease, as well as the nature and stage of organ pathology.
Authors: Edward J Cupler; Kenneth I Berger; Robert T Leshner; Gil I Wolfe; Jay J Han; Richard J Barohn; John T Kissel Journal: Muscle Nerve Date: 2011-12-15 Impact factor: 3.217
Authors: Xiaohua Jiang; Fan Yang; Eugen Brailoiu; Hieronim Jakubowski; Nae J Dun; Andrew I Schafer; Xiaofeng Yang; William Durante; Hong Wang Journal: Arterioscler Thromb Vasc Biol Date: 2007-09 Impact factor: 8.311
Authors: Richard L Sidman; Tatyana Taksir; Jonathan Fidler; Michael Zhao; James C Dodge; Marco A Passini; Nina Raben; Beth L Thurberg; Seng H Cheng; Lamya S Shihabuddin Journal: J Neuropathol Exp Neurol Date: 2008-08 Impact factor: 3.685